Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeneDx Holdings Corp. SEC filings page for ticker WGSWW provides access to the company’s U.S. regulatory disclosures, including current reports, annual and quarterly reports, proxy statements and documents describing its warrant securities. WGSWW represents warrants to purchase one share of GeneDx Holdings Corp. Class A common stock at a specified exercise price per share, and the detailed terms of these warrants are set out in registration statements and related filings.
Through these filings, GeneDx outlines its status as a Delaware corporation, its listing of warrants on The Nasdaq Stock Market LLC, and material corporate events such as changes in the size and composition of its Board of Directors. For example, a Form 8-K describes the appointment of a new Class I director, the increase in board size from seven to eight directors, the application of the Non-Employee Director Compensation Policy, and the company’s intention to enter into a standard form indemnity agreement with the director.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy reports, helping readers understand topics such as warrant terms, governance changes and references to compensation policies without reading every page. Real-time updates from the SEC’s EDGAR system ensure that new GeneDx filings appear promptly, while Form 4 and other insider-related reports can be reviewed to see how directors and officers interact with the company’s securities when such filings are made.
Users interested in GeneDx’s health insights and genomic focus can also use the filings to see how the company describes its activities, risk factors and data resources over time. The combination of original documents and AI-generated explanations makes it easier to interpret complex legal and financial language in the context of the WGSWW warrants and the underlying issuer.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity compensation activity involving restricted stock units and related tax sales. She exercised RSUs covering 30,671 shares of Class A Common Stock at no cost as tranches vested on March 15–16. To cover tax withholding obligations from these vestings, she sold 17,179 shares in open-market transactions at weighted average prices in ranges around $75.74 to $78.16 per share pursuant to a sell-to-cover arrangement, which the filing notes was not a discretionary transaction. Following these tax-related sales, she directly owned 58,447 shares of Class A Common Stock and held RSUs representing up to 414,695 additional shares and options to purchase 107,610 shares, all vesting according to their existing terms.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported routine equity compensation activity. On March 15–16, 2026, he exercised restricted stock units that converted into a total of 11,012 shares of Class A Common Stock at no cost.
On March 16, he then sold 5,706 shares of Class A Common Stock in multiple open-market transactions at weighted average prices in the mid‑$70s. According to the disclosure, these sales were made solely to cover tax withholding obligations under a “sell to cover” arrangement and were not discretionary.
After these transactions, Feeley beneficially owned 27,148 shares of Class A Common Stock and also held RSUs for up to 109,423 shares and options for up to 25,906 shares, all vesting according to their existing schedules.
GeneDx Holdings Corp. chief financial officer Kevin Feeley acquired additional company stock in an insider transaction. On March 6, 2026, he obtained 1,986 shares of GeneDx Class A common stock directly from the company at $88.11 per share under a subscription agreement exempt under Rule 16b-3(d). After this award, his direct ownership increased to 20,660 shares of Class A common stock.
GeneDx Holdings Corp. reported that Chief Executive Officer Katherine Stueland acquired additional company stock. On March 6, 2026, she obtained 3,404 shares of GeneDx Class A common stock directly from the company in an exempt transaction at $88.11 per share, based on that day’s closing price.
Following this acquisition, Stueland directly holds 42,087 shares of GeneDx Class A common stock. The transaction was executed under a Subscription Agreement between GeneDx and Stueland and was structured to qualify for exemption under Rule 16b-3(d).
GeneDx Holdings Corp. reported that investment funds advised by Corvex Management LP, with Keith A. Meister as a control person, made open-market purchases of a total of 169,521 shares of Class A common stock on March 3 and March 5 at prices generally ranging from about $70 to $82 per share.
After these trades, investment funds advised by Corvex directly held 3,228,150 GeneDx Class A shares. CMLS Holdings LLC held 333,144 shares, over which Mr. Meister shares voting and investment discretion, and Mr. Meister’s beneficial holdings also include 20,129 shares issued upon vesting of restricted stock units for his board service. Corvex and Mr. Meister each disclaim beneficial ownership except to the extent of their pecuniary interest.
GeneDx Holdings Corp. reported that Chief Operating Officer Bryan Dechairo acquired 10,430 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Class A common stock for no cash consideration upon settlement.
The award vests over time, with 25% of the RSUs vesting each year on the anniversary of the grant date. The first tranche is scheduled to vest on April 1, 2027, provided Dechairo continues to serve the company on each vesting date. The RSUs have no expiration; they either vest or are cancelled before vesting.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported a mix of equity awards and share sales. On March 3, 2026, he acquired 15,262 shares of Class A Common Stock and 10,865 RSUs at no cost in connection with a performance-based restricted stock unit award tied to revenue and adjusted net income.
On March 4, 2026, he sold a total of 6,187 shares of Class A Common Stock in open-market transactions at weighted average prices in the high-$70 range to cover tax withholding obligations from that vesting. After these transactions, he beneficially owned 18,674 shares, plus RSUs for up to 122,897 shares and options for up to 25,906 shares, subject to vesting.
GeneDx Holdings Corp. chief executive officer Katherine Stueland reported a mix of equity awards and related share sales. On March 3, 2026, she acquired 47,684 shares of Class A Common Stock and 40,418 restricted stock units as a grant tied to a 2025 performance-based award.
On March 4, 2026, she sold a total of 25,459 shares of Class A Common Stock in open-market transactions at weighted average prices between about $77 and $79.64 per share to cover tax withholding obligations from the award’s vesting. After these transactions, she directly owned 38,683 shares, plus RSUs for up to 451,912 shares and options for up to 107,610 shares, all subject to their vesting terms.
GeneDx Holdings Corp. entered into a new Loan Agreement with Blackstone-affiliated lenders providing a $100.0 million term loan funded at closing. The company used the proceeds to repay its prior term loan and plans to direct remaining funds toward balance sheet initiatives, potential reductions of certain operating obligations, and general corporate purposes.
The Term Loan bears interest at Term SOFR plus 4.50%, with a 1.50% SOFR floor, and matures five years from the closing date. It is secured by a first lien on substantially all assets of GeneDx and its guarantor subsidiaries and includes a minimum liquidity covenant of $50 million, mandatory prepayments upon specified events, and optional prepayment subject to yield protection premiums.
GeneDx Holdings Corp. files its annual report describing a genomics business built around exome and whole genome sequencing, including ExomeDx™ and GenomeDx™ tests that hold FDA Breakthrough Device Designation. The company emphasizes one of the world’s largest rare disease datasets, with over 2.5 million tests, including more than 1 million exomes and genomes, and a high proportion of non‑European samples.
Growth priorities focus on pediatric outpatient genetics, NICU rapid genomes, prenatal testing and genomic newborn screening through studies such as GUARDIAN, BEACONS and SeqFirst, plus international expansion via the 2025 Fabric Genomics acquisition. The report details a heavily regulated environment, reimbursement dependence, intense competition, extensive use of AI for interpretation, and broad U.S. and international privacy, laboratory, and fraud‑and‑abuse compliance obligations.